



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/09, 15/12, C07K 14/74	A1	(11) International Publication Number: WO 99/11775 (43) International Publication Date: 11 March 1999 (11.03.99)
(21) International Application Number: PCT/US98/17308 (22) International Filing Date: 20 August 1998 (20.08.98) (30) Priority Data: 08/920,413 29 August 1997 (29.08.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/920,413 (CON) Filed on 29 August 1997 (29.08.97) (71) Applicants (for all designated States except US): PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US). THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street, Boston, MA 02114 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): WALKER, Jürgen, B. [DE/US]; Hirschsprung 1, D-91056 Erlangen (DE). GARBOCZI, David, N. [US/US]; 17613 Parkridge Drive, Gaithersburg, MD 20878 (US).	(74) Agent: TSAO, Y., Rocky; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US). (81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(54) Title: MUTANT MHC CLASS I MOLECULES (57) Abstract Methods of generating a conjugate of MHC class I molecule and a compound via a cysteine residue engineered into the β 2-M subunit. Also featured are uses of the new conjugates.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

MUTANT MHC CLASS I MOLECULES

Statement As to Federally Sponsored Research

The invention was funded in part by National Institutes of Health grant Nos. NOIAI 45218, ROIAI 28568, 5 AI 34247, and CA 60686, and the Department of the Army grant No. DAMD17-94-J-4060. The government may have certain rights in the invention.

Background of the Invention

The major histocompatibility complex ("MHC") plays 10 a central role in the immune system. Antigen-specific T cells recognize antigenic peptides in association with MHC class I or II molecules on the cell surface. Class I molecules consist of two noncovalently associated subunits: a highly polymorphic α heavy chain and a 15 conserved β 2-microglobulin (" β 2-M") light chain. Two of the three extracellular domains of the heavy chain, i.e., domains α 1 and α 2, are folded into a "groove" structure which anchors an antigenic peptide for presentation to T cells.

20 Human class I molecules (or "complexes") have been refolded from *E. coli*-produced heavy chains and β 2-M subunits in the presence of synthetic peptides (Garboczi et al., *Proc. Natl. Acad. Sci. USA*, 89:3429-3433, 1992). The three-dimensional structures of such recombinant 25 complexes as determined by X-ray crystallography are virtually identical to the structure of the class I molecule as isolated from human cells (Madden et al., *Cell*, 75:693-708, 1993; Bjorkman et al., *Nature*, 329:506-512, 1987). Further, subtype A0201* of HLA-A2 produced 30 in *E. coli* and assembled with synthetic HIV-1 nonapeptides has been shown to elicit cytolytic CD8* T cell responses (Walter et al., *Int. Immunology*, 9:451-459, 1997).

- 2 -

The classical class I gene family includes the highly polymorphic human class I molecules HLA-A, -B, and -C, and murine class I (i.e., H-2) molecules D, K, and L. A series of structural relatives (non-classical class I molecules) has been found in humans (e.g., HLA-E, -F, -G, -H, -I, and -J; and CD1) and mice (Q, T, M, and CD1) (Shawar et al., *Annu. Rev. Immunol.*, 12:839-880, 1994). These molecules have the typical structure of an antigen-presenting molecule, where a polymorphic heavy chain is noncovalently associated with the conserved β 2-M subunit. The T cell repertoire reacting with these non-classical ligands has been characterized to only a limited extent.

Summary of the Invention

The invention features a method of preparing a conjugate of an MHC class I molecule and a compound. In this method, one first obtains an MHC class I molecule, where a cysteine residue (i.e. a non-natural or new cysteine residue) has been engineered into its β 2-microglobulin subunit. The compound (e.g., a protein, a carbohydrate, a lipid molecule, or any other organic compound) is then conjugated to the mutant class I molecule specifically via a linkage formed between the sulfhydryl group of the new cysteine residue in the β 2-microglobulin subunit and a functional group of the compound. Alternatively, the compound can be first conjugated to the new β 2-M subunit, and then the subunit is mixed with an α heavy chain (from the same or different species as the β 2-M subunit) in the presence of an appropriate peptide to form a compound-class I conjugate. The cysteine residue is preferably introduced into a region of β 2-M that faces away from the interface between β 2-M and the α heavy chain. Exemplary regions are those corresponding to residues 15-23, 35-53, or 66-97 of SEQ ID NO:1. SEQ ID NO:1 shows the amino acid

- 3 -

sequence of a human β 2-M. Minor sequence variations can exist among β 2-M molecules from different or the same species; and residues from two different β 2-M sequences are said to be corresponding to each other when they are
5 equivalent in function or relative position to the conserved residues in the two β 2-M sequences, or both. The new residue, alone or together with one or more (e.g., two to five) amino acid residues, can be inserted into the β 2-M region without any deletion of the region,
10 or replace one or more (e.g., two to five) residues of the region. For instance, the new cysteine residue can replace a residue that corresponds to serine 52, tyrosine 67, or lysine 91 of SEQ ID NO:1.

The compound can be, for example, a ligand for a
15 multivalent binding molecule, an antibody (e.g., one that is specific for a tumor antigen), a molecule on the surface of a cell (e.g., an antigen-presenting cell or any other hematopoietic cell), or a ligand for a surface receptor of a cell.

20 The new compound-class I conjugates have several uses. For instance, when a multivalent binding molecule is supplied, conjugates of the ligands for the binding molecule with the new, monomeric class I molecules (e.g., ones that consist of an α heavy chain, the new β 2-M, and
25 a peptide associated with the heavy chain) can be multimerized. Multimeric class I molecules can be used to, e.g., label, isolate and quantitate specific T cells. Exemplary multivalent binding molecules are avidin (or a derivative thereof, e.g., streptavidin), whose ligands
30 are biotin and biotin derivatives.

A conjugate of the present invention can also be used to stimulate the immunity of an individual (e.g., a human or a mouse). To accomplish this, a conjugate of a new class I molecule and a cell (e.g., an antigen-
35 presenting cell) is introduced into an individual, and

- 4 -

the conjugate can stimulate the immune cells, particularly T cells specific for the peptide in the conjugate. In this method, the cell and the class I molecule in the conjugate are preferably syngeneic with
5 this individual.

Another conjugate of the present invention can be used to eradicate a tumor (or any other undesired cell) in an individual. In this method, a conjugate of a new class I molecule and an antibody specific for an antigen
10 (or a ligand for a receptor) expressed exclusively or primarily on the cell is introduced into the individual. The α heavy chain in the conjugate can be allogeneic or xenogeneic) to the patient. If the heavy chain is syngeneic to the patient, the class I molecule would be
15 associated with an antigenic peptide that can elicit a strong T cell response.

Use of the new recombinant β 2-M, monomeric and multimeric class I molecules containing the new β 2-M, and the new compound-class I conjugates are also within the
20 scope of the invention.

The new β 2-M eliminates the need for genetically engineering MHC heavy chains to create a chemically reactive site in each of the differing MHC class I molecules. This is a significant advantage in view of
25 the enormous polymorphism of MHC heavy chains.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

Brief Description of the Drawings

30 Figs. 1A-1C are a set of graphs showing the results of flow cytometry analysis of the binding of the phycoerythrin-labeled HLA-A2-SL9 tetramer to human cytotoxic T lymphocyte cells of clones 68A62 (specific for HLA-A2-IV9), 18030 (specific for HLA-A2-SL9), and

- 5 -

63D35 (specific for HLA-B11-AK9), respectively. The cells were also stained with an anti-CD8 monoclonal antibody that was labeled with Cy Chrome, i.e., a fluorescent complex of phycoerythrin and Texas Red.

5 Figs. 2A-2C are a set of graphs showing the results of flow cytometry analysis of the binding of the phycoerythrin-labeled chimeric H-2K^b-SV9 tetramer to mouse cytotoxic T lymphocytes of clones 2F3 (specific for the SV9 peptide bound to H-2K^b), 3C2 (specific for the SV9
10 peptide bound to H-2D^b), and 4G3 (specific for the OVA peptide bound to H-2K^b), respectively. The staining intensity of the H-2K^b-SV9 tetramer is shown in solid line, and the intensity of background fluorescence (i.e., staining with avidin-PE only) is shown in dashed line.

15 Figs. 3A and 3B are a set of graphs showing the binding of a tetrameric MHC-peptide complex (H-2K^b complexed with SV9) to CTLs where K^b is syngeneic (Fig. 3A) or allogeneic (Fig. 3B). Dual parameter contour plots in Figs. 3A and 3C illustrate the phenotype (anti-
20 CD8 versus anti-H-2K^b) of CTLs (double positive) generated in H-2^b mice and CTLs (single positive) generated in H-2^d mice, respectively. The staining intensities with the H-2K^b SV9 reagent (bold line) in Figs. 3A and 3C are shown in Figs. 3B and 3D, respectively, in comparison with
25 background intensity (avidin-PE only, dashed line). Note the comparable shift of fluorescence intensity for syngeneic (Fig. 3B) and the majority of the allogeneic CTL (Fig. 3D).

Detailed Description

30 Methods are provided for preparing a conjugate of a MHC class I molecule and a compound. The MHC class I molecule contains a recombinant β 2-M subunit in which a cysteine residue has been introduced. This residue is preferably introduced into a region of β 2-M that does not

- 6 -

interact with the α heavy chain. Standard mutagenesis techniques can be employed to generate DNA encoding such mutant β 2-M molecules. General guidance can be found in Sambrook et al., *Molecular Cloning, A Laboratory Manual*, 5 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989; and Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience, New York, New York, 1993. The cysteine residue introduced into the β 2-M subunit provides a 10 convenient site for highly selective chemical modification. In addition, coupling between sulfhydryls and certain functional groups is reversible, allowing a compound to be released from the class I molecule to which it has been conjugated.

15 The compound can be linked to the new cysteine residue in the class I molecule via a functional group of its own. Sulfhydryl-reactive functional groups include, but are not limited to, maleimides, pyridyl disulfide, α -haloacyl derivatives (e.g., iodoacetamides), alkyl 20 halides, and aryl halides. Maleimides, alkyl and aryl halides, and α -haloacyls react with sulfhydryls to form thiol ether bonds. Pyridyl disulfides, on the other hand, react with sulfhydryls to produce mixed disulfides. The pyridyl disulfide product is cleavable. A 25 sulfhydryl-reactive crosslinker can also be used, especially when the compound does not contain any sulfhydryl-reactive groups itself. Such a crosslinker possesses two or more different reactive groups that allow its sequential conjugations with two or more other 30 molecules. For instance, crosslinkers that are amine-reactive at one part and sulfhydryl-reactive at another part (e.g., some DOUBLE-AGENT™ crosslinkers available from PIERCE, Rockford, Illinois) can be used to link an amine-containing compound with the mutant class I 35 molecule. By way of example, N-Succinimidyl

- 7 -

3-(2-pyridyldithio)-propionate ("SPDP") is a reversible NHS-ester (i.e., N-hydroxysuccinamide-ester), pyridyl disulfide cross-linker; the amine-reactive NHS-ester in SPDP can be reacted first with a compound of interest, and then with the free -SH group of the new class I molecule. Useful water-soluble SPDP analogs include sulfosuccinimidyl 6-(3-[2-pyridyldithio]propionamido) hexanoate (i.e., sulfonating long chain SPDP analog or Sulfo-LC-SPDP), LC-SPDP, 4-Succinimidylloxycarbonyl- α -methyl- α -(2-pyridyldithio)-toluene ("SMPT"), and sulfosuccinimidyl-6-(α -methyl- α -[2-pyridyldithio]-toluamido) hexanoate ("Sulfo-LC-SMPT"). Additional sulfhydryl- and amine-reactive heterofunctional crosslinkers include succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate ("SMCC"), N- γ -maleimidobutyryloxysulfosuccinimide ester, m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester, sulfosuccinimidyl [4-iodoacetyl] aminobenzoate, and sulfosuccinimidyl 4-[p-maleimidophenyl] butyrate (Pierce, Illinois). Homobifunctional sulfhydryl-reactive crosslinkers such as Bis-maleimido-hexane ("BMH"), 1,4-Di-(3'-[2'-pyridyldithio] propionamido)-butane ("DPDPB"), and 1,5-difluoro-2,4-dinitrobenzene ("DFDNB") can also be used if the compound to be conjugated contains a sulfhydryl.

The α and β 2-M subunits of the MHC class I protein can be from the same or different species (e.g., humans, rats, mice, hamsters, frogs, chickens, etc.). The transmembrane and optionally intracellular domains of the α subunit can be removed to promote proper *in vitro* folding. Methods for obtaining class I heavy chains and β 2-M subunits and for forming monomeric class I-peptide complexes are well known in the art (see, e.g., Zhang et al., *Proc. Natl. Acad. Sci. USA*, 89:8403-8407, 1992; and Garboczi et al., *Proc. Natl. Acad. Sci. USA*, 89:3429-

- 8 -

3433, 1992). The α and β 2-M subunits obtained with a recombinant expression system (e.g., an *E. coli* or baculoviral system) can be refolded separately or together, and then associated in the presence of appropriate peptides (e.g., peptides of about 8-12 amino acid residues in length). Alternatively, the mutant β 2-M subunit can be associated with the α subunit of a pre-formed class I molecule via exchange with the β 2-M subunit in the pre-formed molecules; in such case, no peptide supply is needed in the association reaction if the pre-formed class I molecule is already occupied by a peptide.

In general, the conjugation between the class I protein and the compound is performed after the β 2-M subunit has folded into a native or native-like conformation. In this conformation, the naturally occurring cysteine residues (4 in the heavy chain and 2 in β 2-M) are engaged in stable disulfide bonds and hence not accessible for chemical modification. Therefore, conjugation occurs specifically via the unpaired, surface-exposed cysteine.

Described below are the generation and use of several conjugates of the invention. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, exemplary methods and materials are described below. These exemplary methods and materials are illustrative only and not intended to be limiting. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

- 9 -

In case of conflict, the present specification, including definitions, will control.

I. Cell-Class I Conjugates

The new class I molecule can be conjugated to a
5 compound (e.g., a protein, carbohydrate, or lipid
molecule) on a cell surface via the new cysteine in the
 β 2-M subunit. To accomplish this, the surface of the
cell can be reduced in mild conditions with a reducing
reagent (e.g., dithiothreitol ("DDT"), 2-mercaptoethanol,
10 or 2-mercaptoethylamine·HCl), resulting in reactive sites
(e.g., sulfhydryl groups) on the cell surface. Such
reactive sites will then be reacted directly, or linked
through a bifunctional crosslinker, with the free
sulfhydryl group in the class I molecule. By way of
15 example, the sulfonyl groups attached to the succinimidyl
rings in Sulfo-NHS esters (e.g., Sulfo-LC-SPDP or Sulfo-
SMCC) make these crosslinkers membrane-impermeable and
thus non-reactive with inner membrane proteins; thus,
these crosslinkers are useful in crosslinking the new
20 class I complexes to the cell surface. To determine
optimal conjugation conditions, class I negative cells
such as human HMy2.C1R cells (American Type Culture
Collection CRL-1993) can be used. The density of the
class I peptide complexes anchored on the cell surface
25 can be determined by fluorescence-activating cell sorting
("FACS") analysis, using monoclonal antibodies ("MAb"s)
against the class I molecule.

Peptide-class I complexes conjugated to syngeneic
cells can be used to stimulate the immunity in an
30 individual. To do this, cells derived from this
individual or another with matching MHC haplotypes are
conjugated *in vitro* to the new class I molecules that
have been loaded with antigenic peptides of interest.
Useful cells include, but are not limited to, peripheral

- 10 -

blood lymphocytes taken from a Ficoll density gradient, purified antigen presenting cells such as macrophages/monocytes, dendritic cells, and B cells, or red blood cells. Antigenic peptides of interest are, for example, melanoma-associated immunodominant epitopes derived from melanoma-associated antigens such as MART-1/Melan A, gp 100/Pmel 17, tyrosinase, Mage 3, p15, TRP-1, and β -catenin (Tsomides et al., *International Immunol.*, 9:327-338). The cell conjugates are then introduced into the individual. If the conjugates are used for vaccination, it may be preferred to use antigen-presenting cells as the conjugates' cellular components, since these cells can provide the requisite costimulatory signals for inducing an effective T cell response.

The above immunization strategy allows the control of epitope density and circumvents a variety of problems associated with classical vaccination strategies. For instance, unlike traditional peptide vaccines, the peptides embedded in the present pre-formed, class I peptide complexes are protected from rapid enzymatic degradation or intracellular processing. Traditional peptide vaccines are generally not directly presented by class I molecules on the cell surface; instead, they are typically internalized and processed inside the cell for association with MHC class I molecules. Peptide presentation is thus dependent on a series of intracellular events including the rate of protein degradation, peptide transport, and competition with endogenous peptides.

30 EXAMPLE 1

Direct Conjugation of Class I Complexes with Cells

10⁶ cells in PBS are reduced with 50 μ M DDT for 30 minutes. Consequently, reactive -SH groups on the cell surface are generated. After two washes with PBS, the reduced cells are incubated with the new class I

- 11 -

complexes, resulting in formation of disulfide bonds between the -SH groups in the β 2-M subunits and the -SH groups on the surface of the reduced cells.

EXAMPLE 2

5 Indirect Conjugation of Class I Molecules with Cells

10⁶ cells are suspended in 500 μ l PBS buffer (pH 7.2), and 1 mg of Sulfo-SMCC is added to the cell solution. The incubation proceeds for an hour at room temperature or 30 minutes at 37°C, resulting in a covalent
10 bond between the NHS-ester group in Sulfo-SMCC and a primary amine on the cell surface.

The cells are then washed three times with PBS, and incubated with 0.5 mg of the new recombinant class I protein at 4°C for 1 hour. This step leads to formation
15 of a covalent bond between the free -SH group in the new class I protein and the maleimide group in Sulfo-SMCC.

II. Antibody-Class I Conjugates

The new MHC class I molecule can be specifically targeted to a cell by conjugating to an antibody against
20 an antigen expressed on the surface of the cell. For instance, non-self (e.g., allogeneic) class I molecules conjugated to antibodies specific for a tumor antigen (or any antigen exclusively or primarily expressed by any other undesired tissue) can be attached to tumor tissue
25 (or the undesired tissue) in an individual. The tissue, which now bears foreign MHC molecules, becomes a target of allograft rejection, one of the strongest immune responses known, and can thereby be destroyed.

To elicit a strong immune response against
30 undesired tissue in an individual, an antibody specific for the tissue can also be conjugated to a syngeneic MHC class I molecule that is associated with a potent T cell epitope (e.g., HLA-A2 with the influenza matrix protein 59-68 (ILGFVFTLTV, SEQ ID NO:2), or the influenza B NP

- 12 -

85-94 (KLGEFYNQMM; SEQ ID NO:3)). Such a conjugate can elicit a strong zcytotoxic T cell response that eradicates the undesired tissue.

A variety of monoclonal antibodies can be used to
5 target tumor tissue. Exemplary tumor-associated antigens include, but are not limited to, the Lewis^y-related carbohydrate (found on epithelial carcinomas), the IL-2 receptor p55 subunit (expressed on leukemia and lymphoma cells), the erbB2/p185 carcinoma-related proto-oncogene
10 (overexpressed in breast cancer), gangliosides (e.g., GM2, GD2, and GD3), epithelial tumor mucin (i.e., MUC-1), carcinoembryonic antigen, ovarian carcinoma antigen MOv-18, squamous carcinoma antigen 17-1A, and malignant melanoma antigen MAGE. To extend the serum half life of
15 the MHC-antibody conjugate, the antibody may be humanized if the tumor to be treated is in a human.

The antibody and the MHC components in the present conjugate are conjugated via a covalent bond between the new cysteine residue in the mutant β 2-M and a functional
20 group in the antibody. Intermediary crosslinkers can be used to form the covalent bond. For example, mild oxidation of the sugar moieties in an antibody, using, e.g., sodium metaperiodate, will convert vicinal hydroxyls to aldehydes or ketones. The reaction will be
25 restricted to sialic acid residues when 1 mM sodium metaperiodate is used at 0° C. Subsequent reaction of the aldehyde or ketone group with a sulfhydryl-reactive, hydrazide-containing crosslinker (e.g., 3-(2-Pyridyldithiol)propionyl hydrazide ("PDPH"), 4-(N-maleimidomethyl)cyclohexane-1-carboxylhydrazide
30 hydrochloride, or 4-(4-N-maleimidophenyl)butyric acid hydrazide hydrochloride) results in the formation of a hydrazone bond. The antibody can then be bonded to the new MHC class I molecule via a disulfide bond formed

- 13 -

between the new cysteine residue in the β 2-M and the
sulfhydryl-reactive group in the crosslinker.

Alternatively, mild reduction of an immunoglobulin
can generate free sulfhydryl groups from the disulfide
5 bonds in the hinge region. The sulfhydryl groups can
then be reacted with the free sulfhydryl group of the
class I complex, either directly or via a
homobifunctional crosslinker.

Antibody fragments (e.g., Fab, or F(ab)'₂, both of
10 which lack the glycosylated Fc-portion) can also be
conjugated to the class I complex. F(ab)'₂ fragments can
be generated from antibody molecules by pepsin cleavage;
these fragments can be linked through heterofunctional
cross-linkers such as those that are amine- and
15 sulfhydryl- reactive. Reduction of F(ab)'₂ fragments
generates Fab' fragments, which contain free sulfhydryl
groups. These free sulfhydryl groups can be utilized in
conjugation with the new class I proteins.

Example

20 Generation of an Antibody-Class I Conjugate

The following is an exemplary protocol for
conjugating an antibody to the new MHC class I molecule.

An immunoglobulin G ("IgG") stock solution is
first prepared. It contains 2mg/ml IgG (i.e., 13 μ M) in
25 0.1 M sodium acetate buffer (pH 5.5). The solution is
stored at 0°C. To oxidize the antibody, 1 ml of the IgG
stock solution is mixed with 0.1 ml of cold sodium
metaperiodate solution (stock: 1 mM sodium periodate in
0.1 M sodium acetate buffer, pH 5.5) for 20 min at 0°C in
30 the dark. To stop the oxidation reaction, glycerol is
added to reach a final concentration of 15 mM, and the
incubation proceeds for 5 additional minutes at 0°C.

The IgG sample is then dialyzed over night against
0.1 M sodium acetate buffer (pH 5.5) and concentrated in
35 a CENTRICON 30. The crosslinker PDPH is then added to

- 14 -

the sample to a final concentration of 5 mM, and the sample is incubated for approximately 2 hours at room temperature.

The IgG protein attached to PDPH is purified by
5 HPLC (i.e., high performance liquid chromatography) gel filtration. The HPLC running buffer is 0.1 M Tris-Cl (pH 8). The IgG peak fraction is concentrated with CENTRICON 30 to a final volume of 100 μ l.

To prepare for the class I molecule in the MHC-
10 antibody conjugate, 2 mg of HPLC-purified class I molecule is mildly reduced with a solution containing 0.1 mM DTT and 0.1 M Tris-Cl (pH 8) for 1 hour at room temperature. This will maintain the cysteine in a reduced state. The class I molecule preparation is then
15 purified by HPLC, which removes DTT, and concentrated with CENTRICON 30.

2 mg of the resulting class I molecule is dissolved in 0.5 ml Tris-Cl (pH 8), and added to 0.5 ml of PDPH-modified IgG for overnight incubation at 4°C.
20 The sample is then concentrated with CENTRICON 100 and the MHC-antibody conjugate so obtained, which is approximately 200 kD in size, is purified by HPLC gel filtration or fast protein liquid chromatography. The conjugate is concentrated with CENTRICON 100. Excess
25 peptide (e.g., 5-15 fold molar excess) is added to the concentrated conjugate preparation to stabilize the class I molecule in the conjugate.

III. Multimeric MHC Class I Complexes

The new MHC class I molecule can also be used to
30 form a multimeric MHC class I complex. To do so, one can first obtain a conjugate of a monomeric class I molecule and a ligand for a multivalent binding molecule. The conjugate is formed specifically via a linkage between the sulfhydryl group of the new cysteine in the β 2-M

- 15 -

subunit and a functional group of the ligand. Useful ligands include, but are not limited to, iodoacetyl-LC-biotin, N-(6-[Biotinamido] hexyl)-3'-(2'pyridyldithio)-propionamide ("biotin-HPDP"), and 1-Biotinamido-4-(4'-
5 [maleimidomethyl] cyclohexane-carboxamido)butane ("Biotin-BMCC"). All these biotin derivatives bind to avidin (or a derivative thereof such as streptavidin), a tetravalent molecule. Quantitative blocking of the biotin-binding sites on avidin will render the avidin
10 molecule mono-, bi-, or tri-valent. To generate the conjugate, the α and β 2-M subunits may be allowed to associate in the presence of a peptide of interest to form a stable heteroduplex complex, and then be linked to the ligand; alternatively, the β 2-M subunit may be-first
15 linked to the ligand, and then allowed to associate with the α chain in the presence of the peptide. Multimers of these conjugates can be formed by supplying to these conjugates the multivalent binding molecule to which the ligand binds.

20 The multimeric MHC class I complexes can be used for labeling, quantitation, isolation, and stimulation of T cells. By way of example, the class I multimers can be immobilized on solid-phase matrices, generating an affinity support for the enrichment and isolation of T
25 cells harboring the corresponding antigen receptors. The matrices may be, for instance, agarose gel, beaded polymers, polystyrene plates, glass slides, nitrocellulose membrane, or columns. Immobilization can be effected by non-covalent coupling (e.g., between
30 biotin-avidin/streptavidin interaction, or through magnetic field), or covalent coupling. Certain reversible coupling can allow the captured cells to be eluded from the affinity support. For instance, if the complex is biotinylated with Biotin HPDP, the biotin

- 16 -

moiety can be cleaved from the reacted sulfhydryl with a reducing reagent (e.g., DDT, or β -mercaptoethanol).

The new class I multimers can also be used to characterize T cells that recognize non-classical class I
5 proteins. This is because the new β 2-M can assemble with a wide variety of class I heavy chains, and thus a wide variety of class I multimer probes can be generated using the new β 2-M.

The HLA class I gene family (see, e.g., "Phylogeny
10 of the Major Histocompatibility Complex," in *Immunological Reviews*, 113:1-241, 1990) includes the highly polymorphic class I genes HLA-A, HLA-B and HLA-C, all of which show widespread tissue expression. At least three additional class I genes HLA-E, HLA-F and HLA-G
15 (known as non-classical class I b genes) have been identified; these genes are highly homologous to the classical HLA class I genes, and their polypeptide products are all associated with β 2-M. The family of non-classical class I genes also includes members that do
20 not reside in the MHC genomic complex, such as the subfamily of CD1 genes in both mouse and human, and the mouse thymus leukemia (TL) antigen. Both the TL antigen and CD1 proteins have the typical structure of an antigen-presenting class I molecule. They form
25 heterodimers at the cell surface in which a heavy chain of approximately 38-50 kDa interacts with β 2-M. Another notable non-classical class I gene in mice is the Qa-2 gene. The Qa-2 products, like other class I heavy chains, are associated with β 2-M. The function of these
30 non-classical molecules and the responding T cells are largely unknown.

The ability of β 2-M to associate with diverse heavy chains, and the use of these complexes as signal (e.g., fluorescence)-producing probes, can facilitate the
35 characterization of the T cells that react with these

- 17 -

class I molecules. Information about the corresponding T cells may provide important clues about their specialized function in the immune system.

Monomeric class I complexes conjugated to a solid support are in effect multimerized due to their physical proximity. Thus, the new, monomeric class I complexes conjugated to a solid surface via their free -SH groups can also be used for the same purposes as those described above for multimeric class I complexes.

10 The following examples describe the generation and some uses of several new class I MHC-peptide tetramers. The examples serve to illustrate, but not limit, the new methods and reagents.

In these examples, CTL clones from asymptomatic
15 HIV-1 seropositive patients were established and maintained as described (Johnson et al., *J. Immunol*, 147:1512-1521, 1991). HLA-typing was performed by the Massachusetts General Hospital Tissue Typing Laboratory using standard serological techniques. H-2K^b-SV9 specific
20 CTL clones (syngeneic reactive) were generated in H-2^b mice (K^bD^b) as described (Zhou et al., *J. Immunol Methods*, 153:193-200, 1992). The alloreactive CTL were derived from H-2^{dm2} mice (K^dD^d). All CTLs were maintained in culture by periodic stimulation with RMA-S cells (H-2^b;
25 see, e.g., Townsend et al., *Cold Spring Harb. Symp. Quant. Biol.*, 54 Pt 1:299-308, 1989) loaded with SV9 peptide. CTL clone 4G3, which arose in an H-2K^b mouse, reacts specifically with the ovalbumin octapeptide pOVA (SIINF^{EF}KL; SEQ ID NO:__) in association with H-2K^b (Walden
30 et al., *Proc. Natl. Acad. Sci. USA*, 87:9015-9019, 1990). Cell surface MHC class I molecules on RMA-S cells are largely devoid of peptide unless loaded with peptides from the external medium (Heemels et al., *Ann. Rev. Biochem.*, 64:463-491 1995).

- 18 -

EXAMPLE 1

Production of a Mutant β 2-M

The ribosome-binding site and coding region from a β 2-M expression plasmid (Garboczi et al., Proc. Natl. Acad. Sci. USA, 89:3429-2433, 1992) was cloned into the *E. coli* expression vector pLM1 (Garboczi et al., J. Immunol., 157:5403-5410, 1996) to achieve a higher protein yield. The β 2-M polypeptide is of human origin and has 99 amino acid residues (SEQ ID NO:1) plus one additional methionine residue at the N-terminus that results from the expression in *E. coli*.

A cysteine residue was substituted for the tyrosine 67 residue in the polypeptide by using overlap extension PCRs (i.e., polymerase chain reactions). Four PCR primers were used. The first two were used at the 5' and 3' ends of the β 2-M coding region in the pHN1 plasmid (Garboczi et al., Proc. Natl. Acad. Sci. USA, 89:3429-3433, 1992). These two primers were the 5' primer CTAGAGGATCCTCACACAGGAAACAGAATTTCGAG (SEQ ID NO:4), and the 3' primer CCACCGCGCTACTGCCGCCAGGC (SEQ ID NO:5). The 5' primer introduced a new BamHI site at the 5' end of the β 2-M coding region. The other two primers were used for mutagenesis. They were the top strand primer CTC TTG TAC TGC ACT GAA TTC ACC CCC (SEQ ID NO:6), and the bottom strand primer GAA TTC AGT GCA GTA CAA GAG ATA GAA (SEQ ID NO:7). The new cysteine codon and its complement are underlined.

To generate the cysteine mutation, the following two pairs of primers were first used on the pHN1 template to yield two PCR products: (i) the 5' primer and the bottom strand primer, and (ii) the 3' primer and the top strand primer. The two PCR products were electrophoresed and purified from agarose gel. They were then subjected together to a PCR reaction using the 5' and 3' primers. The final PCR product, which contains the β 2-M coding region with the cysteine mutation, was digested with

- 19 -

BamHI and HindIII and cloned into the same sites in pLM1. The mutated $\beta 2$ -M (i.e., " $\beta 2$ -M(Cys67)") sequence was confirmed by DNA sequencing. Plasmid pLM1 bearing the $\beta 2$ -M(Cys67)-coding sequence was transformed into *E. coli* host BL21(DE3)plysS (Studier et al., *Methods Enzymol.*, 185:60-89, 1990), and a large amount of $\beta 2$ -M(Cys67) was obtained in the form of inclusion body protein.

EXAMPLE 2

Generation of Peptide-MHC Tetramer

10 To generate a class I MHC-peptide tetramer, the tyrosine residue at position 67 (SEQ ID NO:1) of human $\beta 2$ -M was first replaced with a cysteine residue, using standard mutagenesis techniques (see above). There are two naturally occurring cysteine residues in $\beta 2$ -M, which
15 maintain the immunoglobulin structure of $\beta 2$ -M by forming a di-sulfide bond. The new cysteine residue did not bond with any one of the natural cysteine residues, allowing the proper folding of the mutant $\beta 2$ -M (" $\beta 2$ -M(Cys67)"). The free sulfhydryl group in the new cysteine residue was
20 to be used for subsequent chemical modifications of the $\beta 2$ -M subunit.

A monomeric mutant HLA-A2 containing $\beta 2$ -M(Cys67) was then generated. The HLA-A2 heavy chain and the mutant $\beta 2$ -M subunit was obtained in large amounts from *E. coli* host cells transformed with the respective
25 expression vectors. The formation of HLA-A2 (subtype A0201) was initiated in a dilute solution containing a denatured HLA-A2 heavy chain (1 μ M), the denatured $\beta 2$ -M(Cys67) polypeptide (2 μ M), and a synthetic peptide
30 (10 μ M) (see, e.g., Garboczi et al., *Proc. Natl. Acad. Sci. USA*, 89:3429-3433, 1992). The folded MHC-peptide complexes were purified by HPLC (i.e., high performance liquid chromatography) gel filtration. The protein concentration of the purified complex was determined by
35 measuring its optical density. For HLA-A2, 1 A_{280} unit

- 20 -

represents 0.67 mg ml⁻¹ of the protein. The solvent-accessible cysteine 67 in the mutant β 2-M subunit was maintained in a reduced state by 0.1 mM DDT.

The monomeric mutant HLA-A2 was then biotinylated with iodoacetyl-LC-biotin ("ILB"; Pierce), a sulfhydryl-reactive reagent, at the cysteine 67 residue of β 2-M(Cys67). ILB, which was dissolved in N,N-dimethylformamide, was applied at a 5-fold molar excess over the total amount of cysteine in solution. The biotinylation reaction was carried out in Tris-HCl (pH 8.0) and 0.1 mM DDT, and the reaction lasted for 1 hour in the dark at room temperature. Subsequent to the reaction, the volume of the reaction mix was reduced with CENTRICON 30 from 0.5-1 ml to 50 μ l, diluted again in 1 ml Tris-HCl (pH 8.0), concentrated to about 100 μ l, and purified by HPLC gel filtration. In the biotinylated β 2-M(Cys67), the biotin moiety of ILB was separated from the sulfhydryl group of the cysteine 67 residue by the long iodoacetyl-LC arm.

The biotinylated MHC-peptide complexes were purified by HPLC gel filtration. The purified complexes were then multimerized in the presence of deglycosylated avidin-phycoerythrin ("avidin-PE"; Molecular Probes). Deglycosylated avidin-PE binds more than 12 μ g of biotin per mg protein. The resulting tetrameric MHC-peptide complexes were subjected to HPLC gel filtration (TSK G 3000SW, TOSO HAAS, Gel Filtration Standard/BIO-RAD) and then concentrated (CENTRICON 100, Amicon).

EXAMPLE 3

Labeling of T cells with a Peptide-Class I Tetramer

A peptide-MHC class I tetramer was prepared with a HIV-1 gag peptide (i.e., SL9, whose sequence is SLYNTVATL (SEQ ID NO:8)) (Johnson et al., *J. Immunol*, 147:1512-1521, 1991), and a control peptide from HIV reverse transcriptase (i.e., IV9, whose sequence is ILKEPVHGV

- 21 -

(SEQ ID NO:9)) (Tsomides et al., *Proc. Natl. Acad. Sci. USA*, 88:11276-11280 1991). The tetramer was formed by use of avidin-PE, as described in the preceding Example. The binding of the tetramer to cytotoxic T lymphocyte
5 ("CTL") clones with known antigen-binding specificity was monitored by flow cytometry.

Specifically, 5×10^5 cells from each of three human CTL clones specific for HIV-1 derived peptides were pre-stained with an anti-CD8 monoclonal antibody ("mAb") Cy-
10 Chrome (Pharmingen). These three clones, i.e., 68A62 (Tsomides et al., *Proc. Natl. Acad. Sci. USA*, 88:11276-11280, 1991), 18030 (Johnson et al., *J. Immunol.*, 147:1512-1521, 1991), 63D35 are specific for HLA-A2-IV9 (i.e., IV9 presented by HLA-A2), HLA-A2-SL9, and HLA-B11-
15 AK9 (AK9: a HIV-1 reverse transcriptase peptide with the sequence of AIFQSSMTK (SEQ ID NO:10)), respectively.

The pre-stained cells were then incubated with the soluble, PE-labeled tetrameric HLA-A2-SL9 complex at a concentration of 50 $\mu\text{g}/100 \mu\text{l}$ RPMI at 4°C for an hour.
20 The cells were washed and subjected to FACS (i.e., fluorescence-activating cell sorting) analysis using a FACSCAN flow cytometer (Becton Dickinson).

In the FACS analysis, contour plots were based on 10,000 events gated on forward- versus side-scatter. An
25 arbitrarily set boundary on the PE-fluorescence intensity of a negative control was the position of the X-axis quadrant marker, implying that about 80% of the cells can be considered as positive for PE-fluorescence.

The data showed that there was a 10-fold increase
30 in the PE fluorescence intensity when the PE-labeled tetramer stained CTLs of clone 18030 (Fig. 1B), as compared to CTLs of clones 68A82 and 63D35 (Figs. 1A and 1C). Thus, the staining of CTLs by the HLA-A2-SL9 tetramer was specific.

- 22 -

A similar shift of PE fluorescence intensity was observed with CTLs of clone 68A62 when those CTLs were stained with a HLA-A2-IV9 tetramer.

Based on quadrant markers, about 80% of the CTLs specific for HLA-A2-SL9 were stained positively with the phycoerythrin-labeled tetramer.

EXAMPLE 4

Labeling of T Cells with a Hybrid Peptide-Class I Complex

The mutant human β_2 -M in which Tyr 67 has been replaced with a cysteine residue was also shown to bind stably to the heavy chains of the mouse MHC class I molecule K^b.

Tetrameric MHC class I molecules were generated with use of a purified murine H-2K^b ("K^b") heavy chain (Zhang et al., *Proc. Natl. Acad. Sci. USA*, 89:8403-8407, 1992), the mutant human β_2 -M, and SV9, a Sendai virus nucleoprotein-derived peptide (FAPGNYPAL, SEQ ID NO:11) (Kast et al., *Proc. Natl. Acad. Sci. USA*, 88:2283-2287, 1991; and Schumacher et al., *Nature*, 350:703-706, 1991). SV9 promoted folding of the hybrid K^b molecule with an efficiency similar to that of SL9 for promoting folding of HLA-A2. The purified K^b tetramer migrated as a single peak on gel filtration HPLC. The presence of the heavy chain and the β_2 -M subunit in the peak fractions was confirmed by SDS polyacrylamide gel electrophoresis.

5x10⁵ murine CTLs of three different clones were pre-stained with anti-CD8 TRI-COLOR (CALTAG), and then incubated with 50 μ g/100 μ l RPMI PE-labeled chimeric H-2K^b-SV9 tetramer for an hour at 4°C. The three CTL clones 2F3, 3C2, and 4G3 (Walden et al., *Proc. Natl. Acad. Sci. USA*, 87:9015-9019, 1990) are specific for SV9 bound to H-2K^b, SV9 bound to H-2D^b, and OVA (SIINFEKL, SEQ ID NO:12); derived from ovalbumin; Walden et al., *Proc. Natl. Acad. Sci. USA*, 87:9015-9019) bound to H-2K^b, respectively.

- 23 -

(The specificity of the clones is determined on the basis of their lysis of target cells loaded with the corresponding peptide.) After the incubation, the cells were washed and subjected to FACS analysis.

5 Histogram plots (Figs. 2A-2C) for the FACS analysis were based on 10,000 events gated on CD8 fluorescence. As shown in the plots, the K^b-SV9 tetramer stained only 2F3 CTLs (Fig. 2A), but not 3C2 (Fig. 2B) or 4G3 (Fig. 2C) CTLs.

10 In the FACS analysis, markers (M1, M2) were placed to delineate a region of positive intensity relative to a control (Figs. 2B and 2C). Based on these markers, 78% of 2F3 CTLs (Fig. 2A) were found to stain positive with the K^b-SV9 tetramer.

15 EXAMPLE 5

Binding of T Cells by Allogeneic Peptide-Class I Complexes

 Allograft rejection is probably the most powerful T cell reaction known. During such a rejection, an individual's T cells respond strongly to target cells (e.g., a skin graft from a genetically disparate individual of the same species) that bear allogeneic MHC molecules. It has been suggested that the affinities of T cell receptors for MHC-peptide complexes be higher when
20 the MHC component is allogeneic (i.e., non-self) than syngeneic (i.e., self) Sykulev et al., *Proc. Natl. Acad. Sci. USA*, 91:11487-11491, 1994 and Eisen et al., *Advances in Protein Chemistry*, 49:1-56, 1996).

 Figs. 3A-3D compare the reactivity of the K^b-SV9 tetramer with murine CD8⁺ CTLs from two different mouse lines. Briefly, 5x10⁵ syngeneic MHC- and allogeneic MHC- CTLs were stained with anti-CD8 TRI-COLOR and anti-H-2K^b-FITC mAbs (CALTAG), washed and FACS analysed. The CTLs were then incubated with the H-2K^b SV9 tetramer-PE reagent
30 (50 µg/100 µl RPMI, 4°C, 1h), washed, and again subjected

- 24 -

to FACS analysis. All three fluorochromes were excited with an argon laser in a single laser instrument (total of 10,000 events collected).

The CTLs in Fig. 3A were derived from a
5 K^b-positive mouse and the reaction shown is syngeneic;
whereas in Fig. 3C, the CTLs were derived from a K^b-
negative mouse and the reaction shown is allogeneic. The
tetramer bound specifically to CTLs from both mouse lines
(Figs. 3B and 3D), but it distinguished between two
10 subsets in the alloreactive CTLs (Fig. 3D), the better
binding subset amounting to about 12-15% of the total CTL
population. The observed difference in staining
intensities of CTLs (Fig. 3D) might be influenced by
differences in cell surface density of TCR and perhaps
15 CD8 molecules. Assuming a 1:1 ratio of the TCR
heterodimer with the CD3 complex, CD3 and CD8 expression
levels were analyzed. The analysis showed that the
cellular subsets of the allogeneic CTL line that stained
with multimeric K^b-SV9 of different intensities had the
20 same amount of CD8 and CD3 per cell.

Other Embodiments

It is to be understood that while the invention
has been described in conjunction with the detailed
description thereof, the foregoing description is
25 intended to illustrate and not limit the scope of the
invention, which is defined by the scope of the appended
claims. For example, to attach a foreign class I
molecule (e.g., one with an allogeneic or even xenogeneic
heavy chain) to a tumor cell, a ligand for a receptor
30 specifically expressed on the tumor cell, instead of a
tumor-specific antibody, is conjugated to the foreign MHC
class I molecule to direct an alloresponse to the tumor
tissue.

- 25 -

Other aspects, advantages, and modifications are within the scope of the following claims.

- 26 -

What is claimed is:

1. A method of preparing a conjugate of a MHC class I molecule and a compound, the method comprising:
providing a MHC class I molecule, wherein a
5 cysteine residue is introduced into its β 2-microglobulin subunit; and
conjugating the MHC class I molecule and the
compound, specifically via a linkage formed between the
sulfhydryl group of the cysteine residue in the
10 β 2-microglobulin subunit and a functional group of the compound.
2. The method of claim 1, wherein the cysteine residue is introduced into a region corresponding to residues 15-23, 35-53, or 66-97 of SEQ ID NO:1.
- 15 3. The method of claim 2, wherein the cysteine residue is a substitute for a residue corresponding to position 67 of SEQ ID NO:1.
4. The method of claim 1, wherein the compound is a ligand for a multivalent binding molecule.
- 20 5. The method of claim 4, wherein the cysteine residue is a substitute for a residue corresponding to position 67 of SEQ ID NO:1.
6. The method of claim 1, wherein the compound is an antibody.
- 25 7. The method of claim 6, wherein the antibody is specific for a tumor antigen.

- 27 -

8. The method of claim 7, wherein the cysteine residue is a substitute for a residue corresponding to position 67 of SEQ ID NO:1.

9. The method of claim 1, wherein the compound is
5 on the surface of a cell.

10. The method of claim 9, wherein the compound is a protein.

11. The method of claim 9, wherein the cell is an antigen-presenting cell.

10 12. The method of claim 11, wherein the cysteine residue is a substitute for a residue corresponding to position 67 of SEQ ID NO:1.

13. The method of claim 1, wherein the compound is a ligand for a surface receptor of a cell.

15 14. The method of claim 13, wherein the cell is an antigen-presenting cell.

15. The method of claim 14, wherein the cysteine residue is a substitute for a residue corresponding to position 67 of SEQ ID NO:1.

20 16. A method of making a multimeric MHC class I molecule, the method comprising:

providing a conjugate of a monomeric MHC class I molecule and a ligand for a multivalent binding molecule, wherein a cysteine residue is introduced into the
25 β 2-microglobulin subunit of the MHC class I molecule, the conjugate is formed specifically via a linkage between the sulfhydryl group of the cysteine residue in the

- 28 -

β 2-microglobulin subunit, and a functional group of the ligand; and

attaching a plurality of the conjugates, via the ligand, to the multivalent binding molecule to form a
5 multimeric MHC class I molecule.

17. The method of claim 16, wherein the cysteine residue is introduced into a region corresponding to residues 15-23, 35-53, or 66-97 of SEQ ID NO:1.

18. The method of claim 17, wherein the cysteine
10 residue is a substitute for a residue corresponding to position 67 of SEQ ID NO:1.

19. The method of claim 16, wherein the ligand is biotin, and the multivalent binding molecule is streptavidin or avidin.

15 20. A method of making a multimeric MHC class I molecule, the method comprising:

providing a β 2-microglobulin into which a cysteine residue is introduced;

conjugating the β 2-microglobulin and a ligand for
20 a multivalent binding molecule, specifically via a linkage formed between the sulfhydryl group of the cysteine residue in the β 2-microglobulin and a functional group of the ligand;

mixing the conjugate so obtained with an α chain
25 of an MHC class I molecule to form a monomeric MHC class I molecule; and




attaching a plurality of the monomeric MHC class I molecules so obtained to the multivalent binding molecule, via the ligand, to form a multimeric MHC class
30 I molecule.

- 29 -




21. The method of claim 20, wherein the cysteine residue is introduced into a region corresponding to residues 15-23, 35-53, or 66-97 of SEQ ID NO:1.

22. The method of claim 21, wherein the cysteine
5 residue is a substitute for a residue corresponding to position 67 of SEQ ID NO:1.

23. The method of claim 20, wherein the ligand is biotin, and the multivalent binding molecule is streptavidin or avidin.



2/4



3/4




FIG. 3A




FIG. 3B

4/4




FIG. 3C




FIG. 3D

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/17308

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 15/09, 15/12; C07K 14/74

US CL : 435/69.1, 69.7; 530/387.3, 395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 69.7; 530/387.3, 395

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Automated Patent System (APS); key words: major histocompat? cysteine, disulfide, conjugate

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, 4,400,376 A (SANDERSON) 23 August 1983, see entire document.	1-23
Y	US 4,478,823 A (SANDERSON) 23 October 1984, see entire document.	1-23
Y	US 5,130,297 A (SHARMA ET AL.) 14 July 1992, see entire document.	1-23
Y	WEIR, D.M. et al. (ed), HANDBOOK OF IMMUNOLOGY 4th edition: IMMUNOCHEMISTRY, published 1986, Blackwell Scientific Publications, Oxford, UK. pages 3.1-3.13. See pages 3.1-3.13.	1-23
Y	US 5,153,265 A (SHADLE ET AL.) 06 October 1992, see entire document.	1-23



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

30 SEPTEMBER 1998

Date of mailing of the international search report

27 OCT 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Thomas Cunningham

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/17308

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,698,420 (URNOVITZ) 06 October 1987, see entire document.	1-23

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/18909

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 97 35991 A (UNIV JOHNS HOPKINS ;SCHNECK JONATHAN P (US); HERRIN SEAN O (US)) 2 October 1997 see the whole document -----	1-13, 15-26, 28-30, 32,33, 36-38, 41-49, 51,52
P,X	CASARES ET AL.: "ENGINEERING AND CHARACTERIZATION OF A MURINE MHC CLASS II-IMMUNOGLOBULIN CHIMERA EXPRESSING AN IMMUNODOMINANT CD4 T VIRAL EPITOPE" PROTEIN ENGINEERING, vol. 10, no. 11, November 1997, pages 1295-1301, XP002097124 see the whole document -----	1-10,15, 19-26, 32,33, 39, 41-46, 51,52

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 18909

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 24-40
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/18909

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9310220	A	27-05-1993	AU 3220593 A	15-06-1993
WO 9604314	A	15-02-1996	AU 696177 B	03-09-1998
			AU 3403995 A	04-03-1996
			CA 2196085 A	15-02-1996
			EP 0776339 A	04-06-1997
			JP 10503379 T	31-03-1998
WO 9419473	A	01-09-1994	AU 6010294 A	14-09-1994
			US 5717058 A	10-02-1998
US 5420244	A	30-05-1995	NONE	
WO 9426903	A	24-11-1994	AU 6858594 A	12-12-1994
			ZA 9403438 A	20-01-1995
WO 9428871	A	22-12-1994	AU 7101294 A	03-01-1995
WO 9620215	A	04-07-1996	AU 4347696 A	19-07-1996
			CA 2208233 A	04-07-1996
			CN 1171117 A	21-01-1998
			CZ 9701868 A	18-03-1998
			EP 0800534 A	15-10-1997
			HU 77468 A	28-05-1998
			JP 10511652 T	10-11-1998
			PL 320922 A	10-11-1997
			SK 80697 A	10-12-1997
WO 9735991	A	02-10-1997	AU 2422497 A	17-10-1997
			CA 2250166 A	02-10-1997
			EP 0889964 A	13-01-1999



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K	A2	(11) International Publication Number: WO 00/00156 (43) International Publication Date: 06 January 2000 (06.01.2000)
(21) International Application Number: PCT/US99/12825 (22) International Filing Date: 25 June 1999 (25.06.1999) (30) Priority Data: 60/090,849 26 June 1998 (26.06.1998) US (60) Parent Application or Grant TRUSTEES OF DARTMOUTH COLLEGE [/]; O. WADE, William, F. [/]; O. DEMIAN, Douglas [/]; O. WADE, William, F. [/]; O. DEMIAN, Douglas [/]; O. TESKIN, Robin, L. : O.	Published	
(54) Title: METHODS AND COMPOSITIONS FOR MODULATING ANTIGEN-SPECIFIC IMMUNOLOGICAL (HUMORAL) RESPONSES BY TARGETING SUCH ANTIGEN TO APCs IN CONJUNCTION WITH ANTI-CD40 LIGAND ADMINISTRATION (54) Titre: METHODES ET COMPOSITIONS PERMETTANT DE MODULER LES REPONSES IMMUNITAIRES (HUMORALES) SPECIFIQUES A UN ANTIGENE EN CIBLANT LEDIT ANTIGENE SUR DES CELLULES PRESENTATRICES DE L'ANTIGENE EN CONJONCTION AVEC L'ADMINISTRATION DE LIGANDS ANTI-CD-40		
(57) Abstract <p>Methods and compositions are provided which upon administration to a subject in need of such treatment result in enhanced or suppressed immunological responses and in particular enhanced or suppressed humoral (antibody) immune responses to a desired antigen. These methods and compositions include an antigen directly or indirectly attached to an antibody specific for antigen expressed by an antigen-presenting cell and optionally an anti-CD40 antibody. These methods and compositions are particularly useful in the treatment of infectious diseases, such as viral, bacterial or fungal infection, and the treatment and/or prevention of cancer, especially for treatment of aged individuals or other subjects having impaired immune systems, and the treatment of autoimmune diseases, transplant, allergy, inflammatory diseases, wherein suppression of antigen-specific immune response is therapeutically beneficial.</p>		
(57) Abrégé <p>Compositions qui, lorsqu'elles sont administrées à un sujet nécessitant un tel traitement, entraînent l'activation ou la suppression des réponses immunitaires et en particulier des réponses immunitaires humorales (anticorps) à un antigène désiré, et méthodes associées. Lesdites compositions comportent un antigène attaché directement ou indirectement contre un anticorps spécifique à un antigène exprimé par une cellule présentatrice d'antigène et éventuellement un anticorps anti-CD-40. Lesdites méthodes et compositions sont particulièrement utiles pour traiter des maladies infectieuses, telles que des infections virales, bactériennes ou fongiques, et pour traiter et/ou prévenir le cancer, en particulier pour traiter des sujets âgés ou des sujets dont le système immunitaire est détérioré, ainsi que pour traiter des maladies autoimmunes, des transplantations, des allergies et des maladies inflammatoires, pour lesquelles la suppression de la réponse immunitaire spécifique à un antigène est thérapeutiquement bénéfique.</p>		